Aiforia Technologies

The company's core business is providing Software as a Service (SaaS) solutions and expert services to pathologists and scientists in clinical, preclinical, and academic laboratories. Aiforia's platform utilizes deep learning AI to increase the speed, accuracy, and consistency of analyzing complex medical images, particularly in pathology. Its primary product, Aiforia Create, allows users to develop their own AI models for image analysis without needing coding experience. The company serves a global client base, including pharmaceutical companies, research institutions, and healthcare providers like the Mayo Clinic. The business model is subscription-based, with fees determined by usage, cloud storage, and the number of users, which creates high customer stickiness.

Aiforia offers solutions for clinical diagnostics, preclinical research, and veterinary pathology. The platform assists in automating routine tasks and supports pathologists in diagnosing diseases like cancer by analyzing digital tissue and cell samples. For the research market, the software helps in discovering new biomarkers and accelerating drug development. The company's clinical suites, such as those for breast and lung cancer, are CE-IVD marked for diagnostic use in Europe. Aiforia has raised significant funding, including a Series B round in 2021, to expand its global presence and develop new diagnostic platforms.